Toxicity Reduced With MRI-Guided Radiotherapy for Prostate Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, July 24, 2023 -- For patients with prostate cancer, magnetic resonance‐guided daily adaptive stereotactic body radiotherapy (MRg-A-SBRT) is associated with reduced toxicity compared with computed tomography‐guided nonadaptive prostate SBRT (CT-SBRT), according to a systematic review and meta‐analysis published online July 24 in Cancer.
Jonathan E. Leeman, M.D., from the Dana‐Farber Cancer Institute/Brigham and Women's Hospital in Boston, and colleagues conducted a meta-analysis to compare acute toxicity rates associated with MRg‐A‐SBRT and CT‐SBRT for prostate cancer. A total of 29 prospective studies, with 2,547 patients, met the inclusion criteria.
The researchers found that the pooled estimates for acute grade 2 or higher (G2+) genitourinary and gastrointestinal toxicity were 16 and 4 percent, respectively, for MRg-A-SBRT, compared with 28 and 9 percent, respectively, for CT-SBRT. The odds ratios for acute G2+ genitourinary and gastrointestinal toxicities comparing MRg-A-SBRT and CT-SBRT were 0.56 and 0.40, respectively, on meta-regression.
"Because there are multiple technical differences between these approaches, further prospective investigation is needed to pinpoint the specific underlying causes, and in particular the role of daily adaptive planning," the authors write. "Whether late toxicity and cancer control rates differ with the use of MRg‐A‐SBRT compared to CT‐SBRT will require longer follow‐up to determine."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.